David Y. Chen

David Y. Chen

Auto-generated profile, based on publicly available information

David Y. Chen

Division of Dermatology, Washington University School of Medicine, St. Louis, MO, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2002
Verified
Journal Article
Closed access
KHKaren M Hajra
Karen M Hajra
DCDavid Y-S Chen
David Y-S Chen
EFEric Fearon
Eric Fearon

13 January 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ALAlexander X. Lozano
Alexander X. Lozano
ACAadel A. Chaudhuri
Aadel A. Chaudhuri
ANAishwarya Nene
Aishwarya Nene
ABAntonietta Bacchiocchi
Antonietta Bacchiocchi
NENoah Earland
Noah Earland
ANAaron M. Newman
Aaron M. Newman

1 April 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
BDBiplab Dasgupta
Biplab Dasgupta
YYYijun Yi
Yijun Yi
DCDavid Y. Chen
David Y. Chen
JWJason D. Weber
Jason D. Weber
DGDavid H. Gutmann
David H. Gutmann
Individuals with the tumor predisposition syndrome, neurofibromatosis 1 (NF1), are prone to development of nervous system tumors, including neurofibromas and pilocytic astrocytomas. Based on the ability of the NF1 gene product (neurofibromin) to function as a GTPase activating protein for RAS, initial biologically based therapies for NF1-associated tumors focused on the use of RAS inhibitors, but with limited clinical success. In an effort to identify additional targets for therapeutic drug design in NF1, we used an unbiased proteomic approach to uncover unanticipated intracellular signaling pathways dysregulated in Nf1-deficient astrocytes. We found that the expression of proteins involved in promoting ribosome biogenesis was increased in the absence of neurofibromin. In addition, Nf1-deficient astrocytes exhibit high levels of mammalian target of rapamycin (mTOR) pathway activation, which was inhibited by blocking K-RAS or phosphatidylinositol 3-kinase activation. This mTOR pathway hyperactivation was reflected by high levels of ribosomal S6 activation in both Nf1 mutant mouse optic nerve gliomas and in human NF1-associated pilocytic astrocytoma tumors. Moreover, inhibition of mTOR signaling in Nf1−/− astrocytes abrogated their growth advantage in culture, restoring normal proliferative rates. These results suggest that mTOR pathway inhibition may represent a logical and tractable biologically based therapy for brain tumors in NF1.

14 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
APAllegra A. Petti
Allegra A. Petti
SWStephen R. Williams
Stephen R. Williams
CMChristopher A. Miller
Christopher A. Miller
IFIan T. Fiddes
Ian T. Fiddes
SSSridhar N. Srivatsan
Sridhar N. Srivatsan
TLTimothy J. Ley
Timothy J. Ley
Virtually all tumors are genetically heterogeneous, containing mutationally-defined subclonal cell populations that often have distinct phenotypes. Single-cell RNA-sequencing has revealed that a variety of tumors are also transcriptionally heterogeneous, but the relationship between expression heterogeneity and subclonal architecture is unclear. Here, we address this question in the context of Acute Myeloid Leukemia (AML) by integrating whole genome sequencing with single-cell RNA-sequencing (using the 10x Genomics Chromium Single Cell 5’ Gene Expression workflow). Applying this approach to five cryopreserved AML samples, we identify hundreds to thousands of cells containing tumor-specific mutations in each case, and use the results to distinguish AML cells (including normal-karyotype AML cells) from normal cells, identify expression signatures associated with subclonal mutations, and find cell surface markers that could be used to purify subclones for further study. This integrative approach for connecting genotype to phenotype is broadly applicable to any sample that is phenotypically and genetically heterogeneous.

1 September 2006 in Genes & Development
Verified
Journal Article
Closed access
PDF file
STShugaku Takeda
Shugaku Takeda
DCDavid Y. Chen
David Y. Chen
TWTodd D. Westergard
Todd D. Westergard
JFJill K. Fisher
Jill K. Fisher
JRJeffrey A. Rubens
Jeffrey A. Rubens
JHJames J.-D. Hsieh
James J.-D. Hsieh
Taspase1 was identified as the threonine endopeptidase that cleaves mixed-lineage leukemia (MLL) for proper Hox gene expression in vitro. To investigate its functions in vivo, we generated Taspase1−/− mice. Taspase1 deficiency results in noncleavage (nc) of MLL and MLL2 and homeotic transformations. Remarkably, our in vivo studies uncover an unexpected role of Taspase1 in the cell cycle. Taspase1−/− animals are smaller in size. Taspase1−/− mouse embryonic fibroblasts (MEFs) exhibit impaired proliferation, and acute deletion of Taspase1 leads to a marked reduction of thymocytes. Taspase1 deficiency incurs down-regulation of Cyclin Es, As, and Bs and up-regulation of p16Ink4a. We show that MLL and MLL2 directly target E2Fs for Cyclin expression. The uncleaved precursor MLL displays a reduced histone H3 methyl transferase activity in vitro. Accordingly, chromatin immunoprecipitation assays demonstrate a markedly decreased histone H3 K4 trimethylation at Cyclin E1 and E2 genes in Taspase1−/− cells. Furthermore, MLLnc/nc;2nc/nc MEFs are also impaired in proliferation. Our data are consistent with a model in which precursor MLLs, activated by Taspase1, target to Cyclins through E2Fs to methylate histone H3 at K4, leading to activation. Lastly, Taspase1−/− cells are resistant to oncogenic transformation, and Taspase1 is overexpressed in many cancer cell lines. Thus, Taspase1 may serve as a target for cancer therapeutics.

21 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MKMinji Kang
Minji Kang
JAJose Juan Almagro Armenteros
Jose Juan Almagro Armenteros
GGGunsagar S. Gulati
Gunsagar S. Gulati
RGRachel Gleyzer
Rachel Gleyzer
SASusanna Avagyan
Susanna Avagyan
ANAaron M. Newman
Aaron M. Newman
Single-cell RNA sequencing (scRNA-seq) has transformed our understanding of cell fate in developmental systems. However, identifying the molecular hallmarks of potency – the capacity of a cell to differentiate into other cell types – has remained challenging. Here, we introduce CytoTRACE 2, an interpretable deep learning framework for characterizing potency and differentiation states on an absolute scale from scRNA-seq data. Across 31 human and mouse scRNA-seq datasets encompassing 28 tissue types, CytoTRACE 2 outperformed existing methods for recovering experimentally determined potency levels and differentiation states covering the entire range of cellular ontogeny. Moreover, it reconstructed the temporal hierarchy of mouse embryogenesis across 62 timepoints; identified pan-tissue expression programs that discriminate major potency levels; and facilitated discovery of cellular phenotypes in cancer linked to survival and immunotherapy resistance. Our results illuminate a fundamental feature of cell biology and provide a broadly applicable platform for delineating single-cell differentiation landscapes in health and disease.